KNTC1

KNTC1 Full Name

kinetochore associated 1

KNTC1 Introduction

Kinesin family member 5B (KIF5B), also known as kinesin-1 heavy chain or ubiquitous kinesin heavy chain (uKHC), is a plus-end-directed microtubule motor protein that powers the anterograde transport of diverse cellular cargoes along microtubule tracks. Encoded by the KIF5B gene on chromosome 10p11.22, KIF5B is one of three mammalian kinesin-1 heavy chain isoforms (KIF5A, KIF5B, KIF5C), with KIF5B being the ubiquitously expressed isoform. Kinesin-1 is the founding member of the kinesin superfamily and functions as a heterotetramer composed of two heavy chains (providing motor activity) and two light chains (mediating cargo binding and regulating motor activity).

Figure 1. Strcuture of KNTC1.

Motor Mechanism and Intracellular Transport Functions
KIF5B converts the chemical energy of ATP hydrolysis into mechanical work through a conserved motor domain at its N-terminus, which binds microtubules and undergoes a cyclic conformational change coupled to the ATPase cycle. With each ATP hydrolyzed, the motor domain takes an 8-nanometer step toward the microtubule plus end (typically oriented toward the cell periphery), generating forces of 5-7 pN. The central stalk domain mediates heavy chain dimerization through coiled-coil interactions, while the C-terminal tail domain binds kinesin light chains (KLCs) and specific cargo adaptor proteins including Milton (mitochondrial trafficking), JIP1/3 (vesicular trafficking), and huntingtin-associated protein 1 (HAP1). Through these interactions, KIF5B transports mitochondria, lysosomes, secretory vesicles, endosomes, and mRNA-protein complexes. In neurons, KIF5B is critical for axonal transport of synaptic vesicle precursors, mitochondria, and ion channels; its dysfunction leads to axonal transport deficits that are a common feature of many neurodegenerative diseases.

KIF5B in Neurological Disease and Cancer
Mutations in the neuron-specific KIF5A paralog cause hereditary spastic paraplegia type 10 (SPG10) and Charcot-Marie-Tooth disease type 2, illustrating the critical importance of kinesin-1 function in long-distance axonal transport. While KIF5B is not a primary genetic cause of these disorders due to its ubiquitous expression and likely embryonic lethality of loss-of-function mutations, it has been implicated in the pathogenesis of Alzheimer's disease (through its role in transport of amyloid precursor protein and tau), Huntington's disease (through HAP1-mediated transport), and amyotrophic lateral sclerosis. In cancer biology, recurrent KIF5B gene fusions have been identified as oncogenic drivers: the KIF5B-RET fusion in non-small cell lung cancer (NSCLC) and the KIF5B-ALK fusion in a subset of lung adenocarcinomas produce chimeric proteins in which the KIF5B coiled-coil domain drives constitutive dimerization and activation of the RET or ALK kinase domains, respectively. These fusions are therapeutically targetable with RET inhibitors (selpercatinib, pralsetinib) and ALK inhibitors (crizotinib, alectinib), representing a clinical success story in precision oncology.

Alternate Names for KNTC1

KNTC1; kinetochore associated 1; ROD; kinetochore-associated protein 1; Rough Deal homolog, centromere/kinetochore protein;